Clairity Breast uses artificial intelligence to estimate a woman’s five-year breast cancer risk from an existing screening mammogram. Developed by Clairity and led by founder and CEO Dr. Connie Lehman, the FDA-authorized technology is designed to provide risk information rather than diagnose breast cancer.
Key Takeaways
- Clairity Breast uses AI to estimate five-year breast cancer risk from a screening mammogram
- The technology was developed by Clairity, founded and led by Dr. Connie Lehman
- The platform is FDA-authorized for breast cancer risk prediction
- The tool does not diagnose breast cancer or replace radiologists
- AI-generated risk information is intended to complement clinical decision-making
Clairity Breast Introduces AI-Based Breast Cancer Risk Assessment
Clairity Breast provides an AI-based assessment using an existing screening mammogram to estimate a woman’s likelihood of developing breast cancer over a five-year period.
The technology focuses on risk prediction rather than identifying an existing cancer diagnosis. A risk assessment estimates the likelihood of a future condition, while a diagnostic assessment determines whether a disease is currently present.
The distinction also reflects the broader role of breast cancer screening education, which can help women understand the purpose of screening, preventive care and informed healthcare decisions.
Clairity Breast adds another type of information to the screening process by analyzing mammographic data for patterns associated with future risk. The resulting estimate is intended to be considered alongside clinical care rather than treated as a diagnosis.
The technology is FDA-authorized for breast cancer risk prediction. Its authorization applies to that defined risk-assessment function and does not make the system a replacement for clinical evaluation.
AI Analysis Uses Existing Screening Mammograms
Clairity Breast analyzes information from an existing screening mammogram to estimate five-year breast cancer risk. The approach uses imaging already collected as part of breast cancer screening rather than requiring a separate type of imaging examination for the risk assessment.
The mammogram provides the information analyzed by the AI system, which then generates an estimate of future breast cancer risk.
This function differs from identifying an abnormality that may indicate an existing cancer. Cancer detection addresses whether disease may currently be present, while risk prediction estimates the likelihood of developing cancer during a defined period.
Clairity Breast is designed around the second function. Its five-year timeframe gives patients and healthcare professionals a defined period for interpreting the risk estimate.
The output therefore serves as an additional source of risk information derived from screening imaging rather than a cancer diagnosis.
Risk Prediction Is Not a Cancer Diagnosis
Clairity Breast does not diagnose breast cancer. The platform estimates five-year risk, which is different from determining whether cancer is currently present.
That distinction is important when interpreting an AI-generated assessment. A higher or lower risk estimate does not establish whether an individual woman has breast cancer.
The platform’s stated function is limited to risk prediction, and medical decisions continue to require appropriate clinical evaluation and professional judgment.
Five-Year Risk Estimates Add Information Beyond Cancer Detection
The five-year period used by Clairity Breast gives its assessment a specific timeframe. Rather than evaluating an image solely for signs of an existing cancer, the platform estimates the likelihood that breast cancer could develop within the following five years.
That creates a different type of information from the immediate interpretation of a screening mammogram. The screening image remains part of breast cancer detection, while the AI system uses information from that image to generate a separate risk estimate.
A five-year estimate should also be understood as a probability rather than a definitive prediction of an individual woman’s future health. It does not guarantee that breast cancer will or will not develop.
The information generated by the platform is intended to complement clinical decision-making. Healthcare professionals can consider the risk assessment alongside other relevant information when discussing care with patients.
For women undergoing screening, the distinction between detection and risk assessment provides the central context for understanding the technology. Clairity Breast is designed to add information about future risk while remaining separate from cancer diagnosis.
FDA-Authorized Technology Separates Risk Prediction From Diagnosis
Clairity Breast is FDA-authorized for breast cancer risk prediction. Its regulatory status defines the platform around the specific purpose of estimating breast cancer risk from screening mammograms.
Authorization for risk prediction does not change the distinction between prediction and diagnosis. The system remains a risk-assessment tool rather than a method for independently determining whether cancer is present.
Similar boundaries apply to other AI tools in women’s healthcare, where regulated technologies can assist with defined clinical tasks while healthcare professionals remain responsible for broader evaluation and decision-making.
The intended use of an AI medical system is important when interpreting its output. An algorithm developed for risk assessment should be considered within that defined role rather than treated as capable of performing functions outside its authorized purpose.
For Clairity Breast, that means the resulting estimate provides information about future breast cancer risk but does not establish a diagnosis or determine an individual patient’s medical outcome.
Clinical Decisions Remain With Patients and Healthcare Professionals
AI-generated risk information from Clairity Breast is intended to complement clinical decision-making rather than replace it. The platform does not take the place of radiologists or independently diagnose breast cancer.
Radiologists and other healthcare professionals remain responsible for clinical assessment and interpretation. Clairity Breast contributes an estimate of five-year risk based on information contained in the screening mammogram.
The technology should therefore be viewed as an additional source of information rather than an independent medical decision-maker. Its output can contribute to discussions between patients and healthcare professionals while remaining separate from diagnosis and treatment decisions.
For women, the practical distinction is between receiving additional information about future risk and receiving a cancer diagnosis. Clairity Breast is designed to provide the former.
Its use of artificial intelligence does not change that boundary. The system analyzes a screening mammogram and generates a risk estimate, while diagnosis and medical decisions remain clinical functions.
Frequently Asked Questions
What is the AI breast cancer risk tool from Clairity?
Clairity Breast is an AI-powered platform developed by Clairity that estimates a woman’s five-year breast cancer risk from an existing screening mammogram. It is designed for risk prediction rather than cancer diagnosis.
Can AI predict breast cancer risk from a mammogram?
Clairity Breast is designed to analyze information from a screening mammogram and estimate five-year breast cancer risk. The resulting assessment is a risk estimate rather than a determination that cancer is present.
Does Clairity Breast diagnose breast cancer?
No. Clairity Breast estimates breast cancer risk and does not diagnose breast cancer. Determining whether cancer is currently present remains a separate clinical function.
Is Clairity Breast FDA-authorized?
Yes. The platform is described as FDA-authorized for breast cancer risk prediction. Its authorization applies to its risk-assessment function rather than replacing clinical diagnosis.
How does AI-based breast cancer risk assessment differ from cancer detection?
Risk assessment estimates the likelihood of developing breast cancer over a defined period, while cancer detection focuses on identifying disease that may already be present. Clairity Breast is designed for the risk-assessment function.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Readers should consult a qualified healthcare professional regarding breast cancer screening, individual risk factors, and medical decisions.
